In the VOLTAGE-A1 study, neoadjuvant chemoradiotherapy followed by nivolumab in MSS locally advanced rectal cancer showed a higher pathological complete response (pCR) rate in the PD-L1-positive tumor proportion score (TPS) group than in the negative group (75% vs. 17%) (30). The gene discussed is CD274; the disease is rectal cancer.